HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection. 2024

Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
Gilead Sciences, Inc., Foster City, CA, USA.

We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080908 Broadly Neutralizing Antibodies Neutralizing antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent (e.g., HIV) by targeting several epitopes. Broad Neutralizing Antibodies,Broad Neutralizing Antibody,Broad Spectrum Antibodies,Broadly Neutralizing Antibody,Cross-Neutralizing Antibodies,Cross-Neutralizing Antibody,bnAb,bnAbs,Antibodies, Broad Neutralizing,Antibodies, Broad Spectrum,Antibodies, Broadly Neutralizing,Antibodies, Cross-Neutralizing,Antibody, Broad Neutralizing,Antibody, Broadly Neutralizing,Antibody, Cross-Neutralizing,Cross Neutralizing Antibodies,Cross Neutralizing Antibody,Neutralizing Antibodies, Broad,Neutralizing Antibodies, Broadly,Neutralizing Antibody, Broad,Neutralizing Antibody, Broadly,Spectrum Antibodies, Broad
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
January 2016, Expert review of vaccines,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
December 2023, bioRxiv : the preprint server for biology,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
November 2021, Journal of the International AIDS Society,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
March 2016, Trends in immunology,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
November 2007, Current HIV research,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
January 2017, International reviews of immunology,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
March 2017, Virus evolution,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
May 2014, PLoS pathogens,
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
August 2010, Science (New York, N.Y.),
Laurie A VanderVeen, and Lisa Selzer, and Brian Moldt, and Aiyappa Parvangada, and Jiani Li, and Jintanat Ananworanich, and Trevor A Crowell, and Joseph J Eron, and Eric S Daar, and Richard Haubrich, and Romas Geleziunas, and Joshua Cyktor, and John W Mellors, and Christian Callebaut
October 2017, Science (New York, N.Y.),
Copied contents to your clipboard!